Multidrug-resistant bacteria in hematology patients: emerging threats

Future Microbiol. 2016 Jun:11:767-80. doi: 10.2217/fmb-2015-0014. Epub 2016 May 19.

Abstract

Multidrug-resistant (MDR) bacteria, particularly Gram negatives, such as Enterobacteriaceae resistant to third-generation cephalosporins or carbapenems and MDR Pseudomonas aeruginosa, are increasingly frequent in hematology patients. The prevalence of different resistant species varies significantly between centers. Thus, the knowledge of local epidemiology is mandatory for deciding the most appr-opriate management protocols. In the era of increasing antibiotic resistance, empirical therapy of febrile neutropenia should be individualized. A de-escalation approach is recommended in case of severe clinical presentation in patients who are at high risk for infection with a resistant strain. Targeted therapy of an MDR Gram negative usually calls for a combination treatment, although no large randomized trials exist in this setting. Infection control measures are the cornerstone of limiting the spread of MDR pathogens in hematology units.

Keywords: antimicrobial stewardship; combination treatment; de-escalation; febrile neutropenia; infection control; multidrug-resistant bacteria; selective digestive decontamination; β-lactamase inhibitors.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Multiple, Bacterial*
  • Gram-Negative Bacteria / classification
  • Gram-Negative Bacteria / drug effects*
  • Gram-Negative Bacteria / genetics
  • Gram-Negative Bacteria / isolation & purification
  • Gram-Negative Bacterial Infections / drug therapy
  • Gram-Negative Bacterial Infections / microbiology*
  • Hematology / statistics & numerical data
  • Humans

Substances

  • Anti-Bacterial Agents